NASDAQHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading CERT? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a stable management setup with a focus on core competencies, but it is currently loss-making. The thesis is supported by strong recent financial performance, although risks remain elevated due to potential earnings misses.
The market appears to have priced in a level of fragility, as CERT has an expensive valuation compared to peers, with an expectations gap suggesting that investors may not fully believe in its recovery potential. The recent drop in valuation indicates some adjustment to these concerns.
Management is focused on cautious revenue growth and maintaining adjusted EBITDA margins, but there is a near-term risk of missing earnings again, which could impact sentiment. The recent financial performance has been strong, but the company has missed earnings in recent quarters.
The future performance of CERT hinges on guidance from management in upcoming calls and the performance of sector bellwethers like VEEV, BTSG, and TEM. Positive earnings from these companies could provide a favorable backdrop, while negative results could signal trouble ahead.
Over the next 1 to 3 years, CERT's performance will depend on its ability to navigate sector dynamics and manage operational challenges. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. This change is primarily driven by the latest earnings miss, which raises concerns about the company's performance. The company has reaffirmed its guidance, but the recent miss suggests potential challenges ahead.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This will show if the company can grow after selling its Medical Writing business.
Confirms:Q2 revenue growth is below 0% compared to Q2 2025.
Disproves:Q2 revenue growth is 0% or higher compared to Q2 2025.
Why it matters: If it drops below this level, it may show problems after the sale.
Confirms:Adjusted EBITDA margin is below 30% for Q2 2026.
Disproves:Adjusted EBITDA margin is 30% or higher for Q2 2026.
Why it matters: A new CFO can impact financial strategy and investor confidence. The transition is critical.
Confirms one read:Certara announces the appointment of a new CFO by July 14, 2026.
Confirms the other:No new CFO is appointed by the end of July 2026.
Why it matters: If software revenue growth is above 7%, it shows strong demand. This supports future growth.
Confirms:Q2 software revenue growth reported above 7% year over year.
Disproves:Q2 software revenue growth reported below 7% year over year.
Why it matters: A new CFO could signal a shift in financial strategy and execution focus.
Confirms:Announcement of a new CFO appointment.
Disproves:No announcement of a new CFO by the end of Q3 2026.
Why it matters: Service revenue trends will show if the company has fixed its execution problems. This affects growth.
Confirms one read:Service revenue grows year over year in Q2 2026.
Confirms the other:Service revenue declines year over year in Q2 2026.
Why it matters: A big drop in bookings may show that demand for services is getting weaker.
Confirms:Total bookings decline more than 5% year over year in Q2 2026.
Disproves:Total bookings decline less than 5% year over year in Q2 2026.
Why it matters: A new CFO can change how the company handles money after Gallagher left.
Confirms one read:A new CFO is appointed before Gallagher's departure on July 14, 2026.
Confirms the other:No new CFO is appointed by July 14, 2026.
